Please use this identifier to cite or link to this item:
|Title:||Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review||Authors:||Salloum, Antoine
Chebl, Joanna Abi
Chebl, Karen Abi
Kourie, Hampig R
|Affiliations:||Faculty of Medicine||Keywords:||Adverse events
Immune checkpoint inhibitors
|Issue Date:||2022||Publisher:||Future Medicine||Part of:||Immunotherapy||Volume:||14||Issue:||6||Start page:||489||End page:||503||Abstract:||
Aim: This paper presents the reported dermatological adverse events (AEs) associated with approved combinations of immunotherapy with drugs of the same class, or in combination with targeted therapy or chemotherapy. Materials & methods: PubMed was used as an electronic database, and a total of 29 articles were reviewed which reported dermatological AEs following combination therapies with nivolumab, ipilimumab, axitinib, pembrolizumab, lenvatinib, avelumab, atezolizumab, carboplatin, etoposide, paclitaxel, bevacizumab, pemetrexed, cisplatin and durvalumab. Results: The dermatological AEs reported were mutually inclusive and the highest incidence of specific AEs was seen in the following combinations: rash in the nivolumab/ipilimumab and lenvatinib/pembrolizumab combinations, pruritus in the atezolizumab/nab-paclitaxel combination, dry skin and palmar-plantar erythrodysesthesia in the axitinib/pembrolizumab combination, and alopecia and severe skin reactions in the pembrolizumab/carboplatin/paclitaxel combination. Conclusion: Knowledge of such side effects is of benefit when choosing an optimal treatment regimen and should be integrated into the monitoring and follow-up phases of treatment.
|Appears in Collections:||Faculty of Medicine|
Show full item record
checked on Mar 18, 2023
checked on Mar 22, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.